Akero Therapeutics Inc
AKRO48.815USD
+0.445+0.92%
Market hours （ET）Quotes delayed by 15 min
3.89BMarket Cap
LossP/E TTM
More Details of Akero Therapeutics Inc Company
Akero Therapeutics, Inc. is a clinical-stage company. The Company is developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH), a disease without any approved therapies. Efruxifermin (EFX), is its lead product candidate for MASH, which is being evaluated in the ongoing phase IIb SYMMETRY, phase III SYNCHRONY Histology, and phase III SYNCHRONY real-world studies. The phase III SYNCHRONY program builds on the results of two phase IIb clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with cirrhosis due to MASH. EFX is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. EFX is designed to offer convenient once-weekly dosing.
Company Info
Ticker SymbolAKRO
Company nameAkero Therapeutics Inc
IPO dateJun 20, 2019
CEODr. Andrew Cheng, M.D., Ph.D.
Number of employees63
Security typeOrdinary Share
Fiscal year-endJun 20
Address601 Gateway Boulevard, Suite 350
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code94080
Phone16504876488
Websitehttps://akerotx.com/
Ticker SymbolAKRO
IPO dateJun 20, 2019
CEODr. Andrew Cheng, M.D., Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Andrew Cheng, M.D., Ph.D.
Dr. Andrew Cheng, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
306.19K
-8.92%
Dr. Jonathan Young, J.D., Ph.D.
Dr. Jonathan Young, J.D., Ph.D.
Chief Operating Officer, Executive Vice President, Secretary, Co-Founder
Chief Operating Officer, Executive Vice President, Secretary, Co-Founder
192.48K
-1.56%
Mr. Patrick Lamy
Mr. Patrick Lamy
Senior Vice President - Commercial Strategy
Senior Vice President - Commercial Strategy
32.93K
--
Ms. Catriona Yale
Ms. Catriona Yale
Chief Development Officer
Chief Development Officer
25.61K
--
Dr. Yuan Xu, Ph.D.
Dr. Yuan Xu, Ph.D.
Independent Director
Independent Director
9.40K
--
Mr. Mark T. Iwicki
Mr. Mark T. Iwicki
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Graham L. Walmsley, M.D., Ph.D.
Dr. Graham L. Walmsley, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Scott A. Gangloff
Mr. Scott A. Gangloff
Chief Technology Officer
Chief Technology Officer
--
--
Dr. Judy Chou, Ph.D.
Dr. Judy Chou, Ph.D.
Independent Director
Independent Director
--
--
Dr. Seth L. Harrison, M.D.
Dr. Seth L. Harrison, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Andrew Cheng, M.D., Ph.D.
Dr. Andrew Cheng, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
306.19K
-8.92%
Dr. Jonathan Young, J.D., Ph.D.
Dr. Jonathan Young, J.D., Ph.D.
Chief Operating Officer, Executive Vice President, Secretary, Co-Founder
Chief Operating Officer, Executive Vice President, Secretary, Co-Founder
192.48K
-1.56%
Mr. Patrick Lamy
Mr. Patrick Lamy
Senior Vice President - Commercial Strategy
Senior Vice President - Commercial Strategy
32.93K
--
Ms. Catriona Yale
Ms. Catriona Yale
Chief Development Officer
Chief Development Officer
25.61K
--
Dr. Yuan Xu, Ph.D.
Dr. Yuan Xu, Ph.D.
Independent Director
Independent Director
9.40K
--
Mr. Mark T. Iwicki
Mr. Mark T. Iwicki
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
RTW Investments L.P.
9.31%
Janus Henderson Investors
8.87%
Wellington Management Company, LLP
7.45%
BlackRock Institutional Trust Company, N.A.
6.88%
General Atlantic LLC
6.57%
Other
60.94%
Shareholders
Shareholders
Proportion
RTW Investments L.P.
9.31%
Janus Henderson Investors
8.87%
Wellington Management Company, LLP
7.45%
BlackRock Institutional Trust Company, N.A.
6.88%
General Atlantic LLC
6.57%
Other
60.94%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
45.11%
Investment Advisor
32.34%
Hedge Fund
15.98%
Private Equity
8.24%
Research Firm
3.82%
Venture Capital
2.68%
Individual Investor
1.28%
Foundation
0.41%
Pension Fund
0.28%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
489
88.09M
110.50%
+677.60K
2025Q1
495
89.01M
111.79%
+1.41M
2024Q4
453
76.50M
96.29%
-13.73M
2024Q3
445
77.37M
111.97%
-14.20M
2024Q2
428
76.12M
110.88%
-16.59M
2024Q1
421
77.80M
117.45%
+1.74M
2023Q4
401
63.49M
113.86%
-5.60M
2023Q3
387
61.40M
112.62%
-2.96M
2023Q2
363
60.44M
111.44%
+4.13M
2023Q1
350
52.43M
112.99%
-8.33M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
RTW Investments L.P.
7.42M
9.31%
+559.52K
+8.16%
Mar 31, 2025
Janus Henderson Investors
7.07M
8.87%
+1.03M
+17.14%
Mar 31, 2025
Wellington Management Company, LLP
5.94M
7.45%
-1.44M
-19.53%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
5.48M
6.88%
+346.72K
+6.75%
Mar 31, 2025
General Atlantic LLC
5.23M
6.57%
--
--
Mar 31, 2025
T. Rowe Price Associates, Inc.
4.73M
5.94%
+490.10K
+11.55%
Mar 31, 2025
The Vanguard Group, Inc.
4.22M
5.29%
+526.23K
+14.25%
Mar 31, 2025
Deep Track Capital LP
3.21M
4.03%
+1.72M
+115.45%
Mar 31, 2025
State Street Global Advisors (US)
2.49M
3.13%
+158.80K
+6.80%
Mar 31, 2025
UBS Financial Services, Inc.
2.16M
2.71%
+1.78M
+479.92%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Simplify Propel Opportunities ETF
11.49%
Invesco Dorsey Wright Healthcare Momentum ETF
2.99%
ALPS Medical Breakthroughs ETF
2.87%
SPDR S&P Biotech ETF
1.26%
Tema Heart & Health ETF
1.03%
Virtus LifeSci Biotech Clinical Trials ETF
0.9%
Direxion Daily S&P Biotech Bull 3X Shares
0.72%
First Trust NASDAQ Pharmaceuticals ETF
0.6%
Invesco Nasdaq Biotechnology ETF
0.47%
ProShares Ultra Nasdaq Biotechnology
0.47%
View more
Simplify Propel Opportunities ETF
Proportion11.49%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion2.99%
ALPS Medical Breakthroughs ETF
Proportion2.87%
SPDR S&P Biotech ETF
Proportion1.26%
Tema Heart & Health ETF
Proportion1.03%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.9%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.72%
First Trust NASDAQ Pharmaceuticals ETF
Proportion0.6%
Invesco Nasdaq Biotechnology ETF
Proportion0.47%
ProShares Ultra Nasdaq Biotechnology
Proportion0.47%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
